Sumitomo Mitsui Trust Group Inc. Sells 659,728 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Sumitomo Mitsui Trust Group Inc. decreased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 10.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,713,484 shares of the company’s stock after selling 659,728 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 4.72% of 10x Genomics worth $82,046,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TXG. Assenagon Asset Management S.A. bought a new stake in 10x Genomics in the fourth quarter valued at $26,308,000. ARK Investment Management LLC increased its position in 10x Genomics by 15.4% in the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock valued at $242,743,000 after buying an additional 1,436,582 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in 10x Genomics in the 3rd quarter valued at about $27,778,000. FMR LLC raised its stake in 10x Genomics by 2.7% during the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock worth $301,849,000 after buying an additional 357,470 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock worth $8,027,000 after acquiring an additional 277,355 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Citigroup decreased their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. Morgan Stanley lowered their price objective on shares of 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Barclays reduced their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. Finally, JPMorgan Chase & Co. cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, 10x Genomics currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.86.

10x Genomics Price Performance

Shares of 10x Genomics stock opened at $14.25 on Monday. The stock has a fifty day moving average price of $15.06 and a 200-day moving average price of $17.62. The firm has a market cap of $1.72 billion, a PE ratio of -9.31 and a beta of 1.85. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $51.22.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.